intelligence reporter version 7.4 (Unicom Corporation)
90
Structured Review
Unicom Corporation
intelligence reporter version 7.4
Intelligence Reporter Version 7.4, supplied by Unicom Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/intelligence+reporter+version+7%2E4/intelligence+reporter+version+7+5/pm40525252-87-6-5
Average 90 stars, based on 1 article reviews
Intelligence Reporter Version 7.4, supplied by Unicom Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/intelligence+reporter+version+7%2E4/intelligence+reporter+version+7+5/pm40525252-87-6-5
Average 90 stars, based on 1 article reviews
intelligence reporter version 7.4 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022). Article Snippet: Objective: Given the chronic nature of HIV infection and the evolving treatment landscape, it is important to reexamine the impact of HIV medication choice on adherence, treatment satisfaction, and quality of life (QoL) for people with HIV (PWH).. While bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is commonly prescribed, there are few observational data comparing treatment outcomes with other regimens.. This study aimed to compare health care provider (HCP)– and PWH-reported outcomes for individuals prescribed B/F/TAF versus other antiretroviral therapy (ART) regimens. |